Editas Medicine (NASDAQ:EDIT) Receives New Coverage From Analysts at Cantor Fitzgerald
Editas Medicine (NASDAQ:EDIT) Receives New Coverage From Analysts at Cantor Fitzgerald
Stock analysts at Cantor Fitzgerald initiated coverage on shares of Editas Medicine (NASDAQ:EDIT – Get Rating) in a report released on Tuesday, The Fly reports. The brokerage set an "overweight" rating on the stock.
坎托·菲茨杰拉德的股票分析师开始对以下股票进行报道 Editas Medicine（纳斯达克：EDIT — 获取评级） The Fly报道，在周二发布的一份报告中。该经纪公司对该股设定了 “增持” 评级。
EDIT has been the topic of a number of other reports. Bank of America decreased their target price on Editas Medicine from $18.00 to $15.00 and set a "neutral" rating on the stock in a report on Friday, November 18th. Chardan Capital lowered their price target on Editas Medicine from $43.00 to $35.00 and set a "buy" rating on the stock in a report on Thursday, November 17th. Evercore ISI lowered their price target on Editas Medicine to $8.00 in a report on Monday, November 21st. Royal Bank of Canada lowered their price target on Editas Medicine from $32.00 to $14.00 and set a "sector perform" rating on the stock in a report on Friday, November 18th. Finally, Morgan Stanley lowered their price target on Editas Medicine from $8.00 to $7.00 and set an "underweight" rating on the stock in a report on Tuesday, January 24th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $16.86.
编辑一直是许多其他报告的主题。美国银行在11月18日星期五的一份报告中将Editas Medicine的目标价格从18.00美元下调至15.00美元，并对该股设定了 “中性” 评级。Chardan Capital在11月17日星期四的一份报告中将Editas Medicine的目标股价从43.00美元下调至35.00美元，并对该股设定了 “买入” 评级。Evercore ISI在11月21日星期一的一份报告中将Editas Medicine的目标股价下调至8.00美元。加拿大皇家银行在11月18日星期五的一份报告中将Editas Medicine的目标股价从32.00美元下调至14.00美元，并对该股设定了 “行业表现” 评级。最后，摩根士丹利在1月24日星期二的一份报告中将Editas Medicine的目标股价从8.00美元下调至7.00美元，并对该股设定了 “减持” 评级。三位研究分析师对该股进行了卖出评级，八位发布了持有评级，五位对该公司的股票给出了买入评级。根据MarketBeat的数据，该公司的平均评级为 “持有”，平均目标价为16.86美元。
Editas Medicine Trading Up 5.8 %
Editas 药品交易上涨5.8％
Shares of NASDAQ EDIT traded up $0.54 during mid-day trading on Tuesday, reaching $9.89. The company had a trading volume of 2,458,061 shares, compared to its average volume of 1,987,798. The stock has a market cap of $680.04 million, a PE ratio of -3.34 and a beta of 1.90. The company has a 50-day moving average price of $9.23 and a two-hundred day moving average price of $12.51. Editas Medicine has a 1-year low of $7.70 and a 1-year high of $21.59.
纳斯达克EDIT的股价在周二午盘交易中上涨了0.54美元，达到9.89美元。该公司的交易量为2,458,061股，而平均交易量为1,987,798股。该股的市值为6.804亿美元，市盈率为-3.34，beta值为1.90。该公司的50天移动平均价格为9.23美元，两百天移动平均线价格为12.51美元。Editas Medicine创下了7.70美元的1年低点和21.59美元的1年高点。
Hedge Funds Weigh In On Editas Medicine
对冲基金权衡埃迪塔斯医学
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Total Clarity Wealth Management Inc. acquired a new position in shares of Editas Medicine in the 2nd quarter worth approximately $27,000. Covestor Ltd boosted its holdings in shares of Editas Medicine by 9,693.3% in the 1st quarter. Covestor Ltd now owns 1,469 shares of the company's stock worth $28,000 after acquiring an additional 1,454 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Editas Medicine in the 2nd quarter worth approximately $32,000. Quantbot Technologies LP acquired a new position in shares of Editas Medicine in the 1st quarter worth approximately $44,000. Finally, Great West Life Assurance Co. Can acquired a new position in shares of Editas Medicine in the 3rd quarter worth approximately $48,000. 69.67% of the stock is currently owned by institutional investors.
机构投资者和对冲基金最近增加了或减少了在该公司的股份。Total Clarity Wealth Management Inc.在第二季度收购了Editas Medicine股票的新头寸，价值约27,000美元。Covestor Ltd在第一季度将其持有的Editas Medicine股票增加了9,693.3％。Covestor Ltd在上个季度又收购了1,454股股票后，现在拥有该公司1,469股股票，价值28,000美元。罗素投资集团有限公司在第二季度收购了Editas Medicine股票的新头寸，价值约32,000美元。Quantbot Technologies LP在第一季度收购了Editas Medicine股票的新头寸，价值约44,000美元。最后，大西部人寿保险公司Can在第三季度收购了价值约48,000美元的Editas Medicine股票的新头寸。该股票的69.67％目前由机构投资者持有。
About Editas Medicine
关于埃迪塔斯医学
(Get Rating)
（获取评分）
Editas Medicine, Inc engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J.
Editas Medicine, Inc从事基因组编辑技术的开发和商业化。其技术包括聚类、规则间隔的短回文重复（CRISPR）和CRISPR相关蛋白9（Cas9）。该公司由张峰、Jennifer A. Doudna、George McDonald Church、J.
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Editas Medicine (EDIT)
- Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
- Dividend King Sysco: Buying On The Dip
- Is the 1,600% Rise in Genius Group Stock Justified?
- After Further Review, Investors Liked Exxon Mobil's Earnings
- Will Caterpillar Dig Its Way To Another Buying Opportunity?
- 免费获取 StockNews.com 关于 Editas Medicine 的研究报告（编辑）
- Verizon、Charter在过去一个月中呈上升趋势：他们现在买了吗？
- 股息之王 Sysco：逢低买入
- Genius集团股票上涨1,600％是否合理？
- 经过进一步审查，投资者喜欢埃克森美孚的收益
- 卡特彼勒会挖掘另一个买入机会吗？
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Editas《医学日报》的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Editas Medicine及相关公司的最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。